The global veterinary biomarker market size is expected to

New York, Aug. 19, 2022 (GLOBE NEWSWIRE) — announces the release of the report “Global Veterinary Biomarkers Market Size, Share & Industry Trends Analysis Report By Animal Type, By Disease Type, By Product Type, By Application, By Insights and regional forecasts, 2022 – 2028” –
For example, the measurement of a biomarker may reveal the activity of a metabolic pathway or the amount of protein expression that may be linked to the development of a disease such as diabetes, pancreatitis or cancer, to name a few. name a few.

Clinical medicine uses biomarkers specifically for risk assessment, disease diagnosis, prognosis, therapeutic response monitoring and relapse detection. Biomarkers are very essential in medical and veterinary research as they help characterize human and animal diseases. With the increasing importance of human medicine, biomarkers are also of interest in veterinary medicine, where they can help not only in the early identification of disease, but also in the monitoring of disease in patients, during and after the treatment.

Biomarkers may play the most important role in cancer medicine, just as they do in human medicine. A few biomarkers have been studied in veterinary oncology in vitro and in vivo, in particular for canine hemangiosarcoma (HSA). Additionally, a commercial blood test for canine lymphoma (LSA) is currently available. Depending on its intended use, a good veterinary biomarker should have specific properties and characteristics. It must be precise, sensitive and particular.

The biomarker should change depending on the applicable disease and be able to discriminate between patients and healthy controls. The biomarker must also be reliably and reproducibly quantified. For diagnostic purposes, it is best to extract biomarkers from readily available animal body fluids such as blood plasma, urine, sweat, and saliva, as well as other accessible materials such as hair and feces. The correct assessment of clinical responses to therapy and the guidance of treatment program decisions are both made possible by the identification and quantification of biomarkers.

COVID-19 Impact Analysis

The American Veterinary Medical Association says providing veterinary care during the pandemic has proven difficult for veterinarians in the United States. However, veterinary clinics have long been considered a crucial part of the country’s healthcare system. In addition, health systems have focused their resources more on emergency situations, which has impacted diagnostic testing in animals. Additionally, the supply chain for meat and other food products of animal origin has been disrupted during the pandemic. Consequently, less food of animal origin was consumed, which had an impact on the sector.

Market Growth Factors

Growing incidences of zoonotic diseases and research facilitation

The growing prevalence of zoonoses and foodborne diseases will affect the growth of the market. Like COVID-19, about three-quarters of new and emerging infectious diseases in humans are zoonotic, meaning they can spread from animals to humans. Leaders of G-7 countries have called for “affordable and equitable access to diagnostics” as well as strengthening the “One Health” strategy, which brings together veterinary, medical and environmental disciplines in a collaborative effort to combat COVID-19 and future pandemics. . According to estimates made before the current pandemic, zoonoses cause 2.5 billion cases of human illness and 2.7 million deaths per year.

Increase in the use of animal assistance in pet therapy

Pet therapy is a broad term that covers both animal-assisted therapeutic activities and other animal-assisted activities. Dogs or other animals are used in the emerging field of animal-assisted therapy to help individuals recover from or better cope with health issues like heart disease, cancer, and mental health disorders. On the other hand, animal-assisted activities serve a broader function, such as comforting and entertaining nursing home residents. It gained momentum after its successful impact on people suffering from PTSD.

Market restraining factors

Differences in veterinary services between developed and developing countries

Most developing countries even lack adequate human health services. In such cases, the expectation of providing biomarkers on animals is still a futuristic idea. In many sections of developing countries, the question is not how to create new diagnostic tools, drugs or more effective vaccines. Instead, more efficient veterinary service organizational structures are more crucial than improved diagnostic techniques. Another example of more needed services are community animal health workers, who reside in pastoralist communities and provide affordable “first aid” to neighborhood animals for effective disease control.

Animal Type Outlook

On the basis of animal type, the veterinary biomarker market is divided into companion animals (dogs, cats and others) and production animals. The companion animal segment has acquired the highest revenue share in the veterinary biomarker market in 2021. This is a result of both the considerable disease prevalence rates seen in dogs and the increased adoption rates for dogs . He also decisively stated that cats outnumbered dogs as pets.

Product Type Outlook

Based on product type, the veterinary biomarker market is segmented into biomarkers, kits & reagents, and biomarker readers. The biomarkers, kits and reagents segment recorded the maximum revenue share in the veterinary biomarkers market in 2021. This is due to the widespread availability of popular brands of biomarkers and test kits introduced by influential players in the market. To understand disease progression and provide targeted treatments that specifically target the biological indicator of disease, veterinarians choose sensitive and accurate disease diagnosis methods using biomarker test kits.

Application Outlook

Based on applications, the veterinary biomarker market is classified as disease diagnostics, preclinical research, and others. The preclinical research segment witnessed a major revenue share in the veterinary biomarker market in 2021. Indeed, veterinary biomarkers and post-genomic technologies are increasingly being studied and developed. The segment’s expansion prospect is further enhanced by the advanced techniques adopted by major players in the animal health industry to identify new biomarkers or disease indicators.

Disease type outlook

Based on disease type, the veterinary biomarker market is categorized into inflammatory and infectious diseases, turf and landscaping, skeletal muscle diseases, tumors and others. The tumor segment has generated a promising revenue share in the veterinary biomarker market in 2021. Biomarkers will undoubtedly continue to become useful diagnostic tools, especially for conditions like cancer, but a single screening method will not can and should not, on its own, replace an in-depth analysis. physical and diagnostic examination.

Regional outlook

Based on region, the veterinary biomarkers market can be categorized into North America, Europe, Asia-Pacific, and LAMEA. North America procured the highest revenue share in the veterinary biomarker market in 2021. The significant presence of key players, adoption of various strategies developed by key companies to increase market penetration, the Rising research activities, rising diagnostic rates, increasing animal population and rising costs of veterinary care are all contributing factors to the region’s high share.

The market research report covers the analysis of major market players. Key companies profiled in the report include Zoetis, Inc., Merck & Co., Inc., Virbac, IDEXX Laboratories, Inc., MI:RNA Diagnostics Ltd., Mercodia AB, Antech Diagnostics, Inc. (Mars, Inc.) , Avacta Animal Health Limited (Vimian Group), Life Diagnostics, Inc. and Acuvet Biotech.

Scope of the study

Market Segments Covered in the Report:

By animal type

• Companion

o Dogs

o Cats

o Others

• Production

By disease type

• Inflammatory and infectious diseases

• Lawn and landscaping

• Tumor

• Skeletal muscle diseases

• Others

By product type

• Biomarkers, kits and reagents

• Biomarker readers

By app

• Diagnosis of diseases

• Preclinical research

• Others

By geography

• North America

o United States

o Canada

o Mexico

o Rest of North America

• Europe

o Germany

o United Kingdom

o France

o Russia

o Spain

o Italy

o Rest of Europe

• Asia Pacific

o China

o Japan

o India

o South Korea

o Singapore

o Malaysia

o Rest of Asia-Pacific


o Brazil

o Argentina


o Saudi Arabia

o South Africa

o Nigeria

o Rest of the LAMEA

Profiled companies

• Zoetis, Inc.

• Merck & Co., Inc.

• Virbac

• IDEXX Laboratories, Inc.

• MI: RNA Diagnostics Ltd.

• Mercodia AB

• Antech Diagnostics, Inc. (Mars, Inc.)

• Avacta Animal Health Limited (Vimian Group)

• Life Diagnostics, Inc.

• Acuvet Biotech

Unique offers

• Comprehensive coverage

• The largest number of tables and figures on the market

• Subscription-based model available

• Best price guaranteed

• Support for after-sales research provided with 10% free customization
Read the full report:

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.